| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Divisions of Endocrinology, Departments of Medicine/Pediatrics, Harbor-University of California-Los Angeles Medical Center and Research and Education Institute (C.W., R.S.S., N.B.), Torrance, California 90509; Veterans Affairs Medical Center (A.I.), Salem, Virginia 24153; The Johns Hopkins University (A.D.), Baltimore, Maryland 21287; University of Pennsylvania Medical Center (P.J.S.), Philadelphia, Pennsylvania 19104; Veterans Affairs Medical Center, Baylor College of Medicine (G.C.), Houston, Texas 77030; Veterans Affairs Puget Sound Health Care System, University of Washington (A.M.M.), Seattle, Washington 98108; and Duke University Medical Center (T.W.), Durham, North Carolina 27705
Address all correspondence and requests for reprints to: Dr. Christina Wang, Division of Endocrinology, Department of Medicine, Harbor-University of California-Los Angeles Medical Center, 1000 West Carson Street, Torrance, California 90509.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
We conclude that T gel replacement improved sexual function and mood, increased lean mass and muscle strength (principally in the legs), and decreased fat mass in hypogonadal men with less skin irritation and discontinuation compared with the recommended dose of the permeation-enhanced T patch.
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
We have reported that T when applied as a gel over a larger area
of skin in an open system rarely produces problems of skin irritation
(22). We have also shown that this new T gel (AndroGel) formulation can
efficiently and rapidly increase serum T levels into the normal range
in hypogonadal men.3 About 9–14% of T
applied to the skin as the gel is bioavailable. Pharmacokinetic
analyses of T gel vs. T patch showed that the average serum
T levels over the 180-day treatment period were highest in the 100
mg/day T gel group, and these levels were 1.4- and 1.9-fold higher than
those achieved by the 50 mg/day T gel and the T patch
(Androderm) groups, respectively. The daily application of
the gel resulted in steady state serum T pharmacokinetics with dose
proportional increases in serum estradiol and suppression of LH and FSH
levels. Serum 5
-dihydrotestosterone concentrations were elevated,
but 5-dihydrotestosterone to T ratios increased slightly after T gel
application. Daily T gel application provided more flexibility in
dosing, dose proportionality in T gel pharmacokinetics, and less
discontinuation rate than the permeation-enhanced patch (22; see
Footnote 1). We now report the efficacy and safety of 2 doses of T gel
(AndroGel, 50 and 100 mg T/day, contained in 5 and 10 g gel,
respectively) vs. T patch (Androderm, 2 patches
delivering 5 mg T/day) in 227 hypogonadal men. We monitored the effect
of T replacement on sexual function, mood changes, body composition,
muscle strength, red cell indexes, lipid profile, prostate dysfunction
indexes, skin problems, and other potential side-effects.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Hypogonadal men were recruited and studied in 16 centers in the United States. The patients were between 19–68 yr old and had single morning serum T levels at screening of 10.4 nmol/L (300 ng/dL) or less. Previously treated hypogonadal men were withdrawn from T ester injection for at least 6 weeks and from oral or transdermal androgens for 4 weeks before the screening visit. Aside from the hypogonadism, the subjects were in good health, as evidenced by medical history, physical examination, complete blood count, urinalysis, and serum biochemistry. If the subjects were taking lipid-lowering agents or tranquilizers, the doses were stabilized for at least 3 months before enrollment. The subjects had no history of chronic medical illness or alcohol or drug abuse. They had normal rectal examination, prostate-specific antigen (PSA) level of less than 4 ng/mL, and urine flow rate of 12 mL/s or greater before enrollment in the study. They were excluded if they had a generalized skin disease that might affect the T absorption or prior history of skin irritability with Androderm patch. Subjects weighing less than 80% or more than 140% of their ideal body weight were also excluded.
A total of 227 patients were enrolled; 73, 78, and 76 were randomized to receive 50 mg/day T gel (contained in 5 g gel), 100 mg/day T gel (contained in 10 g of gel), or the T patch, respectively. There were no significant group-associated differences in the patients’ characteristics at baseline (age, height, weight, cause of hypogonadism, and previous T treatment). About 3.9–11.0% of the subjects were less than 35 yr of age, 23.3–36.8% were between 35–49 yr of age, 55.1–57.5% were between 50–64 yr of age, and 3.9–8.2% were 65 yr or over in the 3 initial treatment groups. About 35–45% of the patients had primary hypogonadism (Klinefelter’s syndrome, anorchia, or testicular failure), and 15–25% had secondary hypogonadism (Kallman’s syndrome, hypothalamic pituitary disease, or pituitary tumor). Hypogonadism in the remaining men was attributed to aging or normogonadotropic hypogonadism (symptoms of hypogonadism with low serum T but normal LH). Forty-one percent of the subjects had not received prior T replacement.
Study design
The study was a randomized, multicenter (16 centers), parallel study comparing 2 doses of T gel with a T patch. The study was double blind with respect to the T gel dose and open label for the T patch group. For the first 3 months of the study (days 1–90), the subjects were randomized to receive 50 mg/day T gel in 5 g gel, 100 mg/day T gel in 10 g gel, or 2 nonscrotal patches delivering 5 mg/day (T patch). In the following 3 months (days 91–180), the subjects were administered 1 of the following treatments: 50 mg/day T gel, 100 mg/day T gel, 5.0 mg/day T patch, or 75 mg/day T gel in 7.5 g gel. Patients who were applying T gel had a single, preapplication serum T measurement on day 60, and if the levels were within the normal range of 10.4–34.7 nmol/L (300–1000 ng/dL) they remained on their original dose. Patients with T levels less than 10.4 nmol/L and who were originally assigned to apply 50 mg/day T gel and those with T levels more than 34.7 nmol/L who had received 100 mg/day T gel were then reassigned to administer 75 mg/day T gel for days 91–180.
Subjects returned to the study center on days 0 (baseline), 30, 60, 90, 120, 150, and 180 for a clinical examination and skin irritation and adverse event assessments. Fasting blood samples were drawn on all days. Hematology and clinical biochemistry, including electrolytes, glucose, renal and liver function tests, and lipid profile, were performed at all clinic visits.
T gel and patch
Testosterone gel (AndroGel) was manufactured by Besins Iscovesco (Paris, France) and supplied by Unimed Pharmaceuticals, Inc. (Buffalo Grove, IL). The formulation is a hydroalcoholic gel containing 1% (10 mg/g) T. Approximately 250 g gel were packaged in multidose glass bottles that delivered 2.25 g of the gel for each actuation of the pump. Patients assigned to apply 50 mg/day T were given one bottle of T gel and one bottle of placebo gel (vehicle only); those assigned to receive 100 mg/day T gel were dispensed two bottles of the active T gel. On the morning of day 1 of the study, the patients were instructed to depress the pump of one of the bottles once. The gel was applied to the right upper arm/shoulder. Then, using the same bottle, a second dose of gel was delivered and applied to the left upper arm/shoulder. The second bottle was then used, with gel from the actuation of the pump applied to the right abdomen and the second actuation to the left abdomen. Thus, each patient randomized to T gel applied gel to four application sites each day. On the following day, the application sites were reversed. Alternate application sites continued throughout the study. After application of the gel to the skin, the gel dried within a few minutes. Patients washed their hands thoroughly with soap and water immediately after gel application. After 90 days, for the subjects titrated to the 75 mg/day dose of T gel, the patients were supplied with three bottles, one containing placebo and the other two containing T gel. The subjects were instructed to apply one actuation from the placebo bottle and three actuations from a T gel bottle to four different sites of the body as described above. The sites were rotated each day, using the same sequence as that described above.
Testosterone patches (Androderm) delivering 2.5 mg/day T were provided. The patients were instructed to apply two T patches to a clean dry area of skin on the back, abdomen, upper arms, or thighs once per day. Application sites were rotated with approximately a 7-day interval between applications to the same site. T gel or patches were applied at approximately 0800 h each morning for 180 days.
Methods
Body composition (total body mass, lean body mass, fat mass, and percent fat) was measured by dual energy x-ray absorptiometry with Hologic, Inc., 2000 or 4500A series on days 0, 90 and 180. These assessments were performed in 168 of 227 subjects because the Hologic, Inc., dual energy x-ray absorptiometry equipment was not available at 3 of the 16 study centers. All body composition measurements were centrally analyzed and processed by Hologic, Inc. (Waltham, MA). The data for bone mineral density and bone markers will be reported in a subsequent report.
Muscle strength was assessed on days 0, 90, and 180 with the one-repetitive maximum technique in bench press and seated leg press exercises. The one-repetitive maximum technique assesses the maximal force-generating capacity of the muscles used to perform the test. Muscle strength was assessed in 167 of the 227 patients. Four of the 16 centers did not participate in the muscle strength testing because of lack of the required equipment.
Sexual function and mood were assessed by questionnaires the patients answered daily for 7 consecutive days before clinic visits on day 0 and on days 30, 60, 90, 120, 150, and 180 days during gel and patch application. The subjects recorded whether they had sexual day dreams, anticipation of sex, flirting, sexual interaction (sexual motivation parameters) and orgasm, erection, masturbation, ejaculation, and intercourse (sexual performance parameters) on each of 7 days. The value was recorded as 0 (none) or 1 (any) for analyses, and the numbers of days the subjects noted a parameter were summed for the 7-day period. The average of the four sexual motivation parameters was taken as the sexual motivation score, and that of the five sexual performance parameters was used as the sexual performance mean score (0–7). The subjects also assessed their level of sexual desire, sexual enjoyment, and satisfaction of erection using a seven-point Likert-type scale (0–7), and assessed the percentage of full erection from 0–100%. The subjects rated their mood using a 0–7 score. The parameters assessed included positive mood responses (alert, friendly, full of energy, well/good feelings) and negative mood responses (angry, irritable, sad, tired, nervous). Weekly average scores were calculated. The details of this questionnaire were described previously (24, 25, 26).
Skin irritation assessment were measured at every clinic visit using the following scale: 0 = no erythema, 1 = minimal erythema, 2 = moderate erythema with sharply defined borders, 3 = intense erythema with or without edema, and 4 = intense erythema with edema and blistering/erosion. When subjects developed skin irritation, pretreatment with corticosteroid cream was advised. The Prostate Symptom Score were assessed on days 0, 30, and 90 using the International Prostate Symptom Score (I-PSS) (27, 28). The maximum score for I-PSS is 35. Complete blood counts, serum clinical chemistry, and serum PSA levels were measured at each center’s laboratory.
The study protocol was approved by the institutional review board of each study center. Written consent was obtained from each subject.
Statistical analyses
Descriptive statistics for each parameter were calculated. All
data in the figures and tables show the treatment mean
(±SEM) by day for each of the three groups of subjects
based on the treatment pattern from days 0–90 (left panels)
and for each of the five groups from days 91–180 (right
panels). However, as the final treatment groups (five groups) for
the subjects using T gel were no longer randomized, between-group
comparisons were made only up to day 90 using the original treatment
assignments, 50 or 100 mg T gel or T patch, as the independent groups.
The primary model for analysis of the variables was a two-way ANOVA
model, including all subjects as a group with one repeated measure
effect (study day), one independent group effect (treatment), and their
interaction. If none of the effects was statistically significant, then
no further testing was performed. If the study day effect was
significant, then it was tested using contrasts comparing the results
at follow-up visits to baseline measurements. If the treatment effect
was significant, then group means were compared using pairwise methods.
If the interaction was significant, then both the more detailed
evaluation of study day within treatment and treatment differences
within study day was made. Changes in the sexual function variables
were analyzed using equivalent repeated measures models for categorical
variables. Analyses of change from days 0 to 180 within treatment
groups were made within each of the five groups based on pattern using
paired t tests or Wilcoxon’s test. Comparisons resulting in
a P 
0.05 were considered statistically significant.
SAS version 6.12 (SAS Institute, Inc., Cary, NC) was used
for all analyses.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Two hundred and twenty-seven subjects were initially randomized to 73 in the T gel 50 mg/day (in 5 g gel), 78 in the T gel 100 mg/day (in 10 g gel), and 76 in the T patch groups, respectively. At 90 days, dose adjustments were made in the T gel groups based on the preapplication serum T levels on day 60. Twenty subjects in the 50 mg/day T gel group had the T gel dose increased to 75 mg/day, and 20 in the T gel 100 mg/day group had the T gel dose reduced to 75 mg/day. There were 3 patients in the T patch group who were switched to 50 mg/day T gel because of patch intolerance, one 100 mg/day T gel subject was adjusted to receive 50 mg/day, and one 50 mg/day T gel subject had the dose adjusted to 25 mg/day. The number of subjects enrolled in days 91–180 of the study consisted of 51 continuing 50 mg/day T gel, 40 receiving 75 mg/day T gel, 52 receiving 100 mg/day T gel, and 52 continuing on the patch.
T patch compliance, assessed by counting returned patches, was 65% during days 1–90 and 74% during days 91–180 days. The T gel compliance rate, assessed by the weight of the T gel bottles, was over 93% and 96% for 50 and 100 mg T gel groups, respectively, during days 1–90 and remained at that level from days 91–180.
Serum T concentrations
At the screening visit, mean serum T concentrations (single
sample) were 5.9 ± 0.36, 4.1 ± 0.51, 7.7 ± 0.27, and
8.0 ± 0.51 nmol/L, respectively, in the subjects diagnosed with
primary, secondary, normogonadotropic, and aging-related hypogonadism.
At baseline (day 0) mean serum T concentrations (average values over
24 h) were 7.9 ± 0.52, 4.9 ± 0.55, 10.5 ± 0.43,
and 10.7 ± 0.80 nmol/L in the subjects with primary, secondary,
normogonadotropic, and aging-related hypogonadism. These differences in
baseline serum T levels were observed in all three treatment groups.
Although baseline serum T levels were different in the four hypogonadal
subcategories, the responses of sexual function, muscle strength, and
body composition to T treatment were independent of initial diagnostic
classification. Average serum T concentrations over 24 h at
baseline (day 0) and on days 90 and 180 after treatment are summarized
in Table 1
. These results have been
previously reported as a detailed pharmacokinetic report (see
Footnote 1). After transdermal application on day 90, the average serum
T concentration in the 100 mg/day T gel group was 1.4-fold higher than
that in the 50 mg/day T gel group and 1.9-fold higher than that in the
T patch group. Dose adjustment from 50 to 75 mg/day did not increase
the average serum T concentration, but decreasing the dose from 100 to
75 mg/day lowered the average serum T concentration (see Footnote
1).
|
)
At baseline, the sexual motivation and performance scores were
similar across groups. After transdermal T treatment, with all subjects
as a group, sexual motivation showed significant improvement
(P = 0.0001; Fig. 1, top). The change in
the summary score from baseline, however, was not different among
the three treatment groups. The mean improvement in sexual motivation
was at a maximum by day 30. As a group, sexual desire (Fig. 2, top) increased after
transdermal T treatment (P = 0.0001) without intergroup
difference. Sexual enjoyment with a partner (Fig. 2, bottom)
also increased as a group (P = 0.007). This increase
was less in the T patch than in the T gel groups (P =
0.0113). Similarly, the sexual performance score improved significantly
in all subjects as a group (P = 0.0001). The
improvement in sexual performance from baseline values was not
different between transdermal preparations. The maximum effects of T
replacement on sexual performance were observed at the first assessment
(day 30). As a group, the subjects’ self-assessment of satisfaction of
erection (P = 0.0001) and percentage of full erection
(P = 0.0001) were also increased with T replacement
without significant differences between groups (Fig. 3). T dose adjustment on day 90 did not
alter the improvement in sexual function. Those adjusted to 75 mg/day T
gel had responses very similar to those remaining on 50 or 100 mg/day T
gel.
|
|
|
The positive and negative mood summary responses to T replacement
therapy are shown in Fig. 4. All three
treatment groups had similar scores at baseline, and all subjects as a
group showed improvement in positive mood (P = 0.0001;
Fig. 4, top). Similarly, the negative mood summary scores
were similar in the three groups at baseline, and as a group the
responses to transdermal T applications showed significant
decreases (P = 0.0001) without showing between-group
differences (Fig. 4, bottom).
|
The responses of muscle strength testing by the arm/chest and leg
press tests are shown in Fig. 5. There
were no statistically significant differences in arm/chest or leg
muscle strength among the three groups at baseline. In all treatment
groups, the same proportion of subjects less than 45, between 45–65,
and over 65 yr of age completed the muscle strength tests on days 0,
90, and 180. The increase in muscle mass was not affected by the cause
of hypogonadism. In general, muscle strength improved in both arms
and legs in all three treatment groups without intergroup differences
on days 90 and 180. The muscle strength in the leg press exercises on
day 90 increased by 11.6 ± 2.5 kg (P = 0.0001),
13.7 ± 3.4 kg (P = 0.0003), and 12.7 ± 2.7
kg (P = 0.0001) in the T patch, 50 mg T gel, and 100 mg
T gel groups, respectively (Fig. 5, top). The muscle
strength in the arm/chest muscles significantly increased to a much
smaller extent than the legs in the T gel groups [T patch, 1.5 ±
0.8 kg (P = 0.08); 50 mg/day T gel, 2.6 ± 0.7 kg
(P = 0.0009); 100 mg/day T gel, 2.9 ± 0.8 kg
(P = 0.0004); Fig. 5, bottom]. Adjustment
of the dose on day 90 did not significantly affect the muscle strength
responses to transdermal T preparations.
|
At baseline, there were no significant differences in total
body mass, lean mass, percent fat, and fat mass in the three treatment
groups. On day 90, as a group the overall increase in total mass was
significant (P = 0.04). The increase in total mass was
higher in the 100 mg/day T gel group (1.69 ± 0.29 kg) and T patch
group (1.22 ± 0.32 kg) than in the 50 mg/day T gel group
(0.39 ± 0.32 kg; P = 0.01). The increase in total
mass was not significantly different from day 0 in the 50 mg T gel
group. On day 180, these small increases were maintained in all
treatment groups (50, 75, and 100 mg/day T gel and T patch; Fig. 6, top left). The increase in
body mass was mainly due to the increases in lean body mass. After 90
days of T replacement, the increase in lean body mass was significantly
higher in the 100 mg/day T gel group (2.74 ± 0.28 kg;
P = 0.0002) than in the 50 mg/day T gel (1.28 ±
0.32 kg) and T patch (1.20 ± 0.26 kg) groups. On day 180 the
increases in lean body mass were further enhanced or maintained in all
T gel-treated groups (50 mg/day T gel, 1.59 ± 0.39 kg; 50 to 75
mg/day T gel, 2.75 ± 0.97 kg; 100 to 75 mg/day T gel, 3.33
± 0.43 kg; and 100 mg/day T gel, 3.03 ± 0.35, respectively) as
well as in the T patch group (0.99 ± 0.38 kg; Fig. 6, top
right).
|
, bottom left). Correspondingly, on day 90, the percent body
fat was decreased significantly by -1.0 ± 0.3 and -1.8 ±
0.2 in the 50 and 100 mg/day T gel groups, respectively
(P = 0.0018 and P = 0.0001), but not in
the T patch group (-0.4 ± 0.2). At 180 days the decrease in
percent fat remained significantly lower in all T gel groups, but was
not significantly reduced in the T patch group (Fig. 6, bottom
right). Before treatment (on day 0), the total fat mass (r = -0.21; P = 0.0038) and percent body fat (r = -0.26; P = 0.0002) were negatively correlated with baseline serum T levels. At the end of 180 days of T replacement, the increase in lean body mass was positively correlated with the increase in serum T levels on day 180 from baseline 0 (r = 0.25; P = 0.0027). In contrast, decreases in total fat mass (r = -0.18; P = 0.03) and percent fat (r = -0.25; P = 0.0035) were correlated with the increase in the average serum T levels on day 180 from baseline. The cause of the hypogonadism did not affect the change in body composition.
Hgb and Hct
At baseline, there were no differences in the Hgb or Hct levels
among the three groups (Fig. 7). As a
group, both Hgb and Hct increased (P = 0.0001) with
statistically significance across treatment groups (P =
0.0001). On day 90 the mean increase in Hgb and Hct was very small in
the T patch (Hgb, 0.43 ± 0.11 g/dL; Hct, 1.35 ± 0.40%) and
the 50 mg/day T gel (Hgb, 0.46 ± 0.12 g/dL; Hct, 1.38 ±
0.40%) groups. In the 100 mg/day T gel group, both Hct and Hgb
increased significantly on day 90 (mean increase in Hgb, 1.09 ±
0.12 g/dL; in Hct, 3.54 ± 0.39%) and remained increased on day
180 (mean increase in Hgb, 1.27 ± 0.15 g/dL; in Hct, 4.14 ±
0.44%). Decreasing the dose of T gel from 100 to 75 mg/day did not
significantly change this increase (Fig. 7, top and
bottom).
|
Lipid profile and blood chemistry
The serum total, HDL, and low density lipoprotein (LDL)
cholesterol levels at baseline were not significantly different in all
treatment groups. With transdermal T replacement, there were no overall
treatment effects or intergroup differences in serum concentrations of
total, HDL, and LDL cholesterol (Fig. 8)
or triglycerides (data not shown). There was a significant change in
serum total cholesterol concentrations as a group with time
(P = 0.0001); the concentrations on days 30, 90, and
180 were significantly lower than that on day 0.
|
Prostate dysfunction markers
The number of subjects who had urogenital adverse events that the investigators reported to be possibly or probably drug related included none in the T patch group, 7 (9.6%) in the 50 mg/day T gel group, and 4 (5.1%) in the 100 mg/day T gel group. These adverse events included enlarged prostate on digital rectal examination or elevated serum PSA in 8 subjects, penile/testis pain/sensitivity in 2, and varicocele in another. At baseline 9 of 76 subjects in the T patch group, 13 of 73 in the 50 mg T gel group, and 12 of 78 in the 100 mg T gel group had enlarged prostates on digital rectal examination. Of these 4, 8, and 9 subjects had prior testosterone injection (200 mg every 2–3 weeks) for a mean duration of 4.1, 3.2, and 2.7 yr in the T patch, 50 mg T gel, and 100 mg T gel groups, respectively. Mean serum PSA levels were similar in treatment groups at baseline and increased significantly in the 100 mg/day T gel (day 0, 0.89 ± 0.08 ng/mL; day 90, 1.19 ± 0.12 ng/mL; P = 0.008) and 50 mg/day T gel (day 0, 0.88 ± 0.08; day 90, 1.05 ± 0.14 ng/mL; P = 0.05) groups, respectively, without significant change in the T patch group (day 0, 0.89 ± 0.10; day 90, 0.88 ± 0.09 ng/mL) on day 90. The increases in serum PSA remained the same in the T gel groups at the end of treatment (50 mg/day, 1.06 ± 0.1; 100 mg/day, 1.19 ± 0.13 ng/mL). Serum PSA levels were positively correlated with serum T levels before treatment (r = 0.29; P = 0.0001) and 90 days (r = 0.18; P = 0.023) and 180 days (r = 0.17; P = 0.034) after transdermal T replacement.
Serum PSA levels were elevated to above the normal range in 0, 1, and 4
subjects in the T patch, 50 mg/day T gel, and 100 mg/day T gel groups,
respectively (Table 2). One patient (no.
14–05) in the 100 mg T gel group had elevated PSA (5.3 ng/dL on day
150) and dropped out of the study. Ultrasound failed to detect a
lesion, and sextant biopsy was negative for prostate cancer. Four
patients (no. 11–02, 9–19, 3–07, and 4–17) had enlarged prostates
on digital rectal examination, presumably due to benign prostate
hyperplasia (PSA, 4.2, 6.0, 4.6, and 4.7 ng/mL). All four subjects (no.
11–02, 9–19, 3–07, and 4–17) were enrolled in an open label T gel
extension study (total treatment duration, 24 months). Subjects 3–07
and 11–02 had persistent elevated PSA and were discontinued from the
study at 6 and 12 months into the extension study, respectively.
Subject 9–19 had a PSA level of 6.0 ng/dL on day 180, and he was
without symptoms. This subject was referred to a urologist and
discontinued 1 month after enrollment in the extension study. One month
later his PSA level was 2.7 ng/mL. Subject 4–17 had a serum PSA level
of 6.2 at 6 months into the extension study. T gel was discontinued,
and prostate biopsy showed prostate cancer. These data suggested that
elevated PSA to above the normal range and prostate-related adverse
events occurred more frequently in the 100 mg/day T gel group than in
the 50 mg/day T gel and T patch groups.
|
Skin irritations
Minimal skin irritation (erythema) at the application site was noted in three patients (5.7%) in the 50 mg/day T gel group and another 3 (5.3%) in the 100 mg/day T gel group. Skin irritation varying in intensity from minimal to severe (mild erythema to intense erythema with blisters) occurred in 65.8% of patients in the T gel group. Patients were not advised to use pretreatment with corticosteroid cream until skin irritation developed. Because of the skin irritation with the T patch, 16 subjects discontinued the study; 14 of these had moderate to severe skin reactions at the medication site(s).
Other adverse effects
Adverse events (other than prostate or skin problems described above) that were ascribed to be possibly or probably related to T replacement and led to discontinuation from the study included one subject in the 50 mg/day T gel group who had severe depression and was discontinued from the T gel treatment. This patient had prior episodes of depression that he failed to disclose at entry to the study. Another subject discontinued 100 mg/T gel treatment because of complaints of memory loss and sadness. Another patient using 100 mg/day T gel had high blood pressure and was discontinued from the study. One patient was discontinued from T patch because of Hct and Hgb rising progressively to 57.4% and 18.4 mg/dL on day 150 of treatment.
Gynecomastia was reported to occur in one patient receiving 50 mg/day T gel, three receiving 100 mg/day T gel, and none in the T patch group. Two of the patients had preexisting gynecomastia, and one of them underwent a cosmetic mastectomy 2 months after the start of T gel. After surgery, his gynecomastia was not increased with T gel treatment. The other patients had mild gynecomastia requiring no treatment.
The other adverse events considered by the investigators to be possibly related to the T application were uncommon, usually occurring in less than 2% of subjects, and included transient abnormal laboratory tests (liver enzymes and electrolytes), headache, asthma, hypertension, dizziness, anxiety, and nervousness.
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Sexual function, including sexual desire and motivation and sexual performance, increased in all treatment groups at 30 days after initiation of transdermal T and was maintained with continued replacement. These data are similar to those previously reported with T enanthate injections, sublingual/buccal T administration, transdermal patches, and T implants (13, 14, 24, 29, 30, 31, 32, 33, 34, 35, 36). The improvement in sexual function was not related to the dose or the delivery method of T, nor was the improvement related to the serum T levels achieved by the various T preparations. The data suggest that once a threshold (serum T level probably at the low normal range) is achieved, normalization of sexual function occurs. Increasing serum T levels higher to the upper normal range does not further improve sexual motivation or performance.
In parallel with changes in sexual motivation and performance, administration of transdermal T, either patch or gel, improved mood. Positive mood parameters, such as sense of well-being and energy level, improved, and negative mood parameters, such as sadness and irritability, decreased. The improvement in mood was observed on day 30 and was maintained with continued treatment. Similar to our previous report and those of others, the improvement in mood parameters was not dependent on the magnitude of increase in the serum T levels (29, 36). Once the serum T increased into the low normal range, maximal improvement in mood parameters occurred. Thus, the responsiveness in sexual function and mood in hypogonadal men in response to T therapy appeared to be dependent on reaching a threshold of serum T at the low normal range. As this study was not designed as a placebo-controlled trial, the possibility of a placebo effect on sexual function and mood had not been excluded. Previously reported and unpublished data from our laboratory showed that sexual function and mood were not significantly changed when hypogonadal or normal men were administered placebo (37).
In this study muscle strength was measured by a one-repetitive maximum technique using chest and leg press exercises. The subjects did not participate in any exercise training. The results showed an improvement in muscle strength at 90 and 180 days, more in the legs than the arms, which was not different across treatment groups or on the different days of assessment. There were large variations between subjects and groups, and the possibility of a training effect could not be excluded. Our findings were similar to those reported previously with injectable T, transdermal patch, and sublingual T preparations in young hypogonadal men (25, 38, 39, 40). Improvement in grip strength as well as hamstring and quadriceps work was also reported in elderly men with low serum T levels administered T enanthate injections (41, 42, 43, 44). In another report in which muscle strength was assessed by dynamometer, no change in the strength of knee extension or flexing occurred when transdermal T patches were administered for 36 months in elderly men (17). The increase in muscle strength after androgen replacement may be related to increased fractional muscle protein synthesis (37, 44). Available data, including those from this study, do not clearly support a dose-related response in muscle strength. However, different studies employed different methods of assessment, and the elderly might respond differently than young hypogonadal men (40).
In contrast, the increase in lean body mass and the decrease in fat mass associated with T replacement therapy showed significant correlations with the serum T level attained by the T patch and the different doses of T gel. T gel administered at 100 mg/day increased lean mass more than the T patch and 50 mg/day T gel. The changes in body composition were not affected by the initial diagnosis. The changes were apparent on day 90 after treatment and were maintained or enhanced on day 180. These changes were not due to fluid retention observed after T replacement, because accumulation of water occurs early within the first few weeks. Lean mass was not measured until 3 months and was sustained for 6 months. Changes in body composition were significant even though the subjects were withdrawn from prior T therapy for only 6 weeks. The increase in lean mass after T replacement was very similar to those previously reported in young and elderly hypogonadal men (17, 24, 38, 39, 40, 41, 42, 43, 45). The decreases in fat mass and percent body fat were also related to the serum T level achieved and were different across the treatment groups. The T patch group did not show a decrease in percent body fat or fat mass after 180 days of treatment, which may be related to the lower mean serum T levels achieved. Treatment with T gel (50–100 mg/day) for 90 days reduced percent body fat and fat mass. This decrease was maintained in the 50 and 75 mg/day groups at 180 days, but was further lowered with continued treatment with the higher dose of the T gel (100 mg/day). In the prior studies of hypogonadal men, T replacement resulted in a decrease in fat mass in some studies using injectable or transdermal T (39, 45), but not in others administering injectable or sublingual T (25, 38). The differences in the results could be due to the less sensitive methodologies used in assessment of fat mass or to the lower average serum levels of T achieved by the sublingual preparation.
Monitoring of safety parameters showed an increase in Hct and Hgb levels in all treatment groups. The mean increases in Hct and Hgb levels were minimal with the T patch and 50 mg/day T gel groups and were more marked in the T gel higher dose (100 mg/day) group. Analyses of the data from individual subjects showed that about 20% of the subjects in the higher dose T gel group had a Hct that was elevated to above the normal range on day 180 of treatment. Only one subject in the T patch group was discontinued from the study because of rising Hct. The other blood parameters, lipid profile, and liver or renal function tests showed no consistent changes with T replacement. The changes in red cell indexes were consistent with the anticipated effect of T replacement therapy (13, 24).
Serum PSA concentrations showed the anticipated small rises with both doses of T gel replacement, but not with T patch. These PSA levels plateaued after day 90. In 5 (4 in the 100 mg/day T gel group and 1 in the 50 mg/day T gel group) of the 227 subjects, PSA rose above the upper range of 4 ng/mL. Most of these subjects had enlarged prostates suggestive of benign prostate hyperplasia. All subjects were discontinued from the open label T gel extension study because of persistence of elevated serum PSA levels. In 1 of these subjects (100 mg/day group), prostate biopsy showed prostate cancer. Serum PSA was weakly related to the serum T levels before replacement and those achieved by the dose of T delivered to the body. As T has not been shown to induce prostate cancer, we presume that the elevation of PSA in the T treatment protocol either unmasked asymptomatic prostate cancer and led to biopsy due the increased PSA level or the cancer finding was coincidental to treatment. The prostate symptom scores and the uroflow rates were not significantly changed by T replacement in any treatment group.
Tolerability of the daily application of T gel at the tested dosages was much better than that of the permeation- enhanced T patch. Only 5.5% of subjects had minimal erythema after gel application. Skin irritation, some relatively severe, occurred in about 66% of the subjects using the permeation-enhanced T patch, which resulted in discontinuation of the study in 16 subjects. The open system and the lower concentration of alcohol in the T gel formulation markedly reduced skin irritation, resulting in better tolerability and continuation rate of T replacement therapy.
We have shown in this study that T gel is more effective in increasing lean body mass and decreasing body fat than the recommended T patch regimen, with comparable effects on sexual function, mood, and muscle strength. The differential effects of T gel compared to T patch on lean body mass and body fat may be related to the higher blood levels of T and dihydrotestosterone attained with T gel. Increasing the dose delivered by T patches from 5 to 10 mg/day might increase blood androgen levels and improve response, but perhaps at the risk of more skin irritation. The relative lack of skin irritation coupled with high compliance make T gel a more favorable transdermal androgen delivery method than T patch.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 The Testosterone Gel Study Group includes: S. Berger,
Chicago Center for Clinical Research (Chicago, IL); E. Dula, West Coast
Clinical Research (Van Nuys, CA); J. Kaufman, Urology Research Options
(Aurora, CO); G. P. Redmond, Center for Health Studies (Cleveland,
OH); S. Scheinman and H. W. Hutman, South Florida Bioavailability
Clinic (Miami, FL); S. L. Schwartz, Diabetes and Glandular Disease
Clinic, P.A. (San Antonio, TX); C. Steidle, Northeast Indiana Research
(Fort Wayne, IN); J. Susset, MultiMed Research (Providence, RI); G.
Wells, Alabama Research Center, L.L.C. (Birmingham, AL); and R. E.
Dudley, S. Faulkner, N. Rohowsky, G. Ringham, W. Singleton, J.
Longstreth, and K. Zunich, Unimed Pharmaceuticals, Inc.
(Deerfield, IL).
3 Swerdloff, R. S., C. Wang, G. Cunningham, A. Dobs,
A. Iranmanesh, A. Matsumoto, P. Snyder, T. Weber, N. Berman, and T-gel
Study Group, submitted for publication.
Received February 15, 2000.
Revised April 20, 2000.
Accepted May 12, 2000.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
-Methyl-19-nortestosterone maintains sexual behavior and mood in
hypogonadal men. J Clin Endocrinol Metab. 84:3556–3562.This article has been cited by other articles:
 |
|
 |
|
  P. E. Knapp, T. W. Storer, K. L. Herbst, A. B. Singh, C. Dzekov, J. Dzekov, M. LaValley, A. Zhang, J. Ulloor, and S. Bhasin Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1135 - E1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I-C. Yu, H.-Y. Lin, N.-C. Liu, R.-S. Wang, J. D. Sparks, S. Yeh, and C. Chang Hyperleptinemia without Obesity in Male Mice Lacking Androgen Receptor in Adipose Tissue Endocrinology, May 1, 2008; 149(5): 2361 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Coviello, B. Kaplan, K. M. Lakshman, T. Chen, A. B. Singh, and S. Bhasin Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 914 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Almeida, B. B. Yeap, G. J. Hankey, K. Jamrozik, and L. Flicker Low Free Testosterone Concentration as a Potentially Treatable Cause of Depressive Symptoms in Older Men Arch Gen Psychiatry, March 1, 2008; 65(3): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
|
), 50
mg/day T gel (
), and 100 mg/day T gel (•). Based on the serum T
levels, the dose of T gel was adjusted up or down (from days 91–180)
to 75 mg/day if the serum T level was below or above the adult male
range, respectively. The right panel shows the subjects
in the final five treatment groups (three original treatment groups
plus the additional two groups of subjects whose T gel doses were
adjusted): 50 to 75 mg/day T gel (
) and 100 to 75 mg/day T gel
(
).
